Friday Apr 11
Navidea Pharmaceuticals Inc. Analyst Report: Long Term Market...
Its core product, Lymphoseek, a small-molecule radiopharmaceutical used in lymphatic mapping procedures, helps physician identify and target the lymph nodes that drain from a primary tumor that contain cancer cells.
Navidea Announces Presentation of Study Findings of Manocept Platform ...
Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the University of California, San Francisco presented results at the 2014 American Association for Cancer Research conference, April 5-9, 2014 in San Diego, CA, highlighting the potential ... (more)
Navidea Continues To Execute, When Will The Stock Follow?
To be blunt, Navidea Biopharmaceuticals has been a poor performer over the past year.
Navidea Biopharmaceuticals Provides Update on European Marketing...
Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that today it held an update meeting with the Committee for Medicinal Products for Human Use of the European Medicines Agency for the pending Marketing Authorization Application of Lymphoseek Injection.
Navidea Biopharmaceuticals Announces Presentation of LymphoseekA ...
Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results of a three-year, voluntary follow-up study of Lymphoseek Injection conducted in patients who participated in a Phase 3 clinical trial of the product.